Headlines
EU drugs regulator backs higher dose of Novo's Wegovy
Published by Global Banking & Finance Review®
Posted on December 12, 2025
1 min readLast updated: January 20, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on December 12, 2025
1 min readLast updated: January 20, 2026
EU supports Novo's Wegovy 7.2 mg dose, showing significant weight loss in trials. Approval is pending in other regions.
Dec 12 (Reuters) - Novo Nordisk said on Friday the European Medicines Agency's committee has issued a positive opinion for a 7.2 mg dose of weight-loss drug Wegovy, providing an option for greater weight loss.
In a 1,407-patient trial, adults with obesity but without diabetes who took the 7.2 mg dose lost an average 20.7% of body weight, and about one in three achieved weight loss of 25% or more, with safety and tolerability consistent with the approved 2.4 mg dose, Novo said.
The higher dose is also under review in the U.S., the UK and several other countries.
(Reporting by Puyaan Singh in Bengaluru; Editing by Shinjini Ganguli)
Wegovy is a prescription medication developed by Novo Nordisk for weight management in adults with obesity. It is administered as an injection and is designed to help individuals lose weight and maintain weight loss.
The European Medicines Agency (EMA) is a regulatory agency responsible for the evaluation and supervision of medicinal products in the European Union. It ensures that medicines are safe and effective for public use.
Explore more articles in the Headlines category
